NATCO PHARMA
Back to Balance Sheet
|
NATCO PHARMA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹944 Cr | ₹973 Cr | ₹683 Cr | ₹710 Cr | ₹526 Cr |
What is the latest Total Current Liabilities ratio of NATCO PHARMA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹944 Cr |
| Mar2024 | ₹973 Cr |
| Mar2023 | ₹683 Cr |
| Mar2022 | ₹710 Cr |
| Mar2021 | ₹526 Cr |
How is Total Current Liabilities of NATCO PHARMA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹944 Cr | -3.01 | |
| Mar2024 | ₹973 Cr | 42.41 | |
| Mar2023 | ₹683 Cr | -3.84 | |
| Mar2022 | ₹710 Cr | 35.16 | |
| Mar2021 | ₹526 Cr | - | |
Compare Total Current Liabilities of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹17,131.8 Cr | -4.6% | 12.4% | 23.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹432,000.0 Cr | -0.4% | 5.3% | 13.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹161,076.0 Cr | -4.3% | -6.3% | 12.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹148,510.0 Cr | 0.4% | 8.2% | 44.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,921.0 Cr | 0.5% | 1.8% | 16.4% | Stock Analytics | |
| CIPLA | ₹106,150.0 Cr | -0.8% | -2.6% | -9.2% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | -4.6% |
12.4% |
23.2% |
| SENSEX | -5.5% |
-11.5% |
0.3% |
You may also like the below Video Courses